Small study aims to unlock what makes chemo patients feel truly cared for
NCT ID NCT07536945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will interview 10 to 20 adults receiving chemotherapy as outpatients at a Turkish hospital. Researchers want to understand how patients perceive nursing care that is tailored to their individual needs, values, and lifestyle. The goal is to identify what matters most to patients and how personalized care might help them manage side effects and stick with treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help hospitals design more personalized nursing care for chemotherapy patients, potentially improving their comfort and treatment experience.
- What could go wrong
- This is a very small, early-stage observational study with only 10-20 participants at one hospital. Results may not apply to other settings or patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients receiving ongoing treatment at the Outpatient Chemotherapy Unit of Yalova Training and Research Hospital
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Continuing treatment at the Outpatient Chemotherapy Unit of the relevant hospital. * Voluntarily agreeing to participate in the study. * Being over 18 years of age. * Being proficient in Turkish. * Exclusion Criteria: * Not receiving ongoing treatment at the Outpatient Chemotherapy Unit of the relevant hospital. * Declining to participate in the study voluntarily. * Unwillingness to answer questions or lack of cooperation during the interview.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Of Yalova
Yalova, Yalova, 77200, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breathing pattern calm chemotherapy anxiety and improve sleep?
- Can a game teach chemotherapy patients to protect their skin?
- MRI 'Fingerprint' may reveal which head and neck tumors vanish with Pre-Surgery therapy
- Which PICC insertion method causes fewest complications?
- Can a simple blood test outsmart prostate cancer?
- Can adding radiation at the right time boost immunotherapy for aggressive lung cancer?